Century Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPSC research report →
Companywww.centurytx.com
Century Therapeutics, Inc. , a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- CEO
- Brent Pfeiffenberger
- IPO
- 2021
- Employees
- 140
- HQ
- Philadelphia, PA, US
Price Chart
Valuation
- Market Cap
- $194.78M
- P/E
- -1.81
- P/S
- 0.00
- P/B
- 0.74
- EV/EBITDA
- -1.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.23%
- ROIC
- -37.34%
Growth & Income
- Revenue
- $109.16M · 1556.76%
- Net Income
- $-9,580,000 · 92.43%
- EPS
- $-0.11 · 93.17%
- Op Income
- $-15,040,000
- FCF YoY
- 5.05%
Performance & Tape
- 52W High
- $3.04
- 52W Low
- $0.43
- 50D MA
- $2.31
- 200D MA
- $1.33
- Beta
- 1.56
- Avg Volume
- 1.21M
Get TickerSpark's AI analysis on IPSC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Pfeiffenberger Brent | other | 31,172 |
| May 4, 26 | Carr Douglas | sell | 264 |
| Dec 9, 25 | Murphy Martin Patrick | other | 88,000 |
| Dec 9, 25 | Murphy Martin Patrick | other | 0 |
| Apr 1, 26 | Cowan Chad | other | 1,365 |
| Mar 12, 26 | Carr Douglas | sell | 7,043 |
| Mar 12, 26 | Russotti Gregory | sell | 10,076 |
| Mar 11, 26 | Pfeiffenberger Brent | other | 55,397 |
| Mar 11, 26 | Cowan Chad | other | 1,431 |
| Mar 9, 26 | Russotti Gregory | sell | 479 |
Our IPSC Coverage
We haven't published any research on IPSC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IPSC Report →